Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ACELYRIN, INC.

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Leadership Transition
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
From Acelyrin, Inc.
Via GlobeNewswire
Tickers SLRN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.